论文部分内容阅读
本文报道长程干扰素(IFN)治疗骨髓增生性疾病中血小板增多的效果。31例患者(男9例,女22例,平均年龄70岁)其中真性红细胞增多(真红)12例,原发性血小板增多症(ET)9例,原发性骨髓纤维化(髓纤)及慢性粒细胞白血病(CML)各5例。IFN治疗前中位观察期为1年,其中9例曾行细胞毒药物或胶体-~(198)金治疗。血小板为945(751-1930)×10~9/L rIFN-α-2c(比活性3.2×10~6U/L),皮下注射,诱导期用量为25±9MU/周。缓解后开始维持疗法12个月(第Ⅰ期),用量为17±9MU/周。第Ⅰ期维持治疗结束后,一组随机接受第Ⅱ期治
This article reports the effect of long-acting interferon (IFN) on thrombocytosis in myeloproliferative disease. Thirty-one patients (9 males and 22 females, average age 70 years) included 12 cases of polycythemia vera (true red), 9 cases of essential thrombocythemia (ET), primary myelofibrosis And chronic myeloid leukemia (CML) in 5 cases. The median pre-IFN observation period was 1 year, of which 9 had cytotoxic drugs or colloidal gold ~ 198. Platelet 945 (751-1930) × 10 ~ 9 / L rIFN-α-2c (specific activity 3.2 × 10 ~ 6U / L), subcutaneous injection, the induction period of dosage of 25 ± 9MU / week. After remission began to maintain therapy for 12 months (Phase Ⅰ), the amount of 17 ± 9MU / week. After the first phase of maintenance treatment, a group of randomized to the second phase of governance